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This paper aimed at investigating the expression and methylation profiles of SOX2, a gene coding for the stem cell-related
transcription factor SOX2, in endometrial carcinomas. By methylation-specific polymerase chain reaction (MS-PCR), the
methylation status of SOX2 promoter region in 72 endometrial carcinomas and 12 normal endometrial samples was examined.
Methylated allele was found in 37.5% (27/72) of endometrial carcinomas but only in 8.3% (1/12) of normal endometrial,
significantly more frequent in cancers (P = .0472). SOX2 mRNA level was significantly reduced in endometrial carcinoma
compared with nonneoplastic endometrium (P = .045). A significant correlation between SOX2 mRNA expression and
hypermethylation of SOX2 was found (P = .024). Hypermethylation of SOX2 tended to be more frequently found in type II serous
or clear cell adenocarcinoma. SOX2 methylation was also significantly correlated with shorter survival of patients (P = .046). In
conclusion, epigenetic mechanisms may play a crucial role on the transcriptional regulation of SOX2 and loss of SOX2 expression
may be related to endometrial carcinogenesis.
1. Introduction
Endometrial cancer is the most common cancer found in
the female genital tract worldwide [1]. Although endometrial
cancers generally show favorable prognosis, the incidence
is on the rising trend in North America, Europe, and Asia
[2, 3]. There are two major types of endometrial carcinomas
exhibiting diﬀerent histopathology, cell biology, clinical
course, and underling genetic alterations [4]. Approximately
70–80% endometrial cancers show endometrioid diﬀerenti-
ation and were designated as Type I carcinomas. They are
often preceded by premalignant endometrial hyperplasia,
which is presumably caused by long-duration unopposed
oestrogenic stimulation. Type I carcinomas generally have
favorable outcome. Common genetic changes of Type I
carcinomas include mutations of K-RAS and PTEN genes,
microsatellite instability (MSI) and alteration of beta-catenin
[4]. Type II carcinomas are poorly diﬀerentiated. In contrast
to Type I carcinomas, these tumors are not oestrogen driven
and often arise in a background of atrophic endometrium.
Type II carcinomas also exhibit a more aggressive clinical
course and poorer prognosis than Type I carcinomas.
Common genetic changes include mutations of TP53 and
CDH1 (E-cadherin) genes [4]. Despite the recent advances
in molecular diagnostics, the most important factors in
predicting patient prognosis remain to be tumor grade, stage,
and subtypes [5, 6].
Sox proteins are transcription factors related by a
79-amino acid high-mobility-group (HMG) DNA-binding
domain that was first identified in the mammalian Sry pro-
tein [7]. They take up various roles in neural development,
including neural stem cell maintenance, glial specification,
and lineage-specific terminal diﬀerentiation [8]. More than
20 members of the SOX gene family have been identified in
mammals [9]. Among them, SOX2 was first found crucial
for maintaining the stemness of neural stem cells and
then of embryonic stem cells. In conjunction with OCT3/4
and NANOG, SOX2 is considered a master regulator of
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mammalian embryogenesis and part of a complex network
of transcription factors that aﬀects both pluripotency and
diﬀerentiation in embryonic stem cells [10]. In fact, forced
expression of OCT3/4, SOX2, c-MYC, and KLF4 was suﬃ-
cient to induce stem cell-like pluripotency in adult fibroblast
[11] and CD34+ blood cell [12].
SOX2 is dysregulated in many human cancers but its
role may vary in diﬀerent kinds of malignancy. SOX2
was found to be frequently downregulated in intestinal
metaplasia of stomach [13] and gastric cancers [14]. Ectopic
overexpression of SOX2 could inhibit cell growth through
cell-cycle arrest and apoptosis in gastric epithelial cells
[14]. In contrast, SOX2 and OCT3/4 were overexpressed
in esophageal squamous cancer and significantly associated
with higher histological grade and poorer clinical survival
[15]. SOX2 overexpression was also observed in small cell
lung cancer [16], basal cell-like breast carcinomas [17], and
glioma [18]. Overexpressed SOX2 may promote cell pro-
liferation and tumorigenesis of breast cancer cells through
enhancing the G1/S transition of cell cycle [19]. Similarly,
silencing SOX2 in glioblastoma tumor-initiating cells leads
to stop of proliferation and loss of tumorigenicity [20].
Recently, our team was the first to report loss of SOX2
and hypermethylation in the promoter region of SOX2
in trophoblastic diseases including hydatidiform mole and
choriocarcinoma [21].
CpG island hypermethylation is a common event in
the development of the gynecologic cancers [22]. Our team
has previously demonstrated the hypermethylation of RAS-
related genes in endometrial carcinomas in association with
distinct clinicopathological parameters [23]. To the best of
our knowledge, there is no report on the methylation status
of SOX2 gene in endometrial cancers. Therefore, we decided
to study the methylation and expression status of SOX2 in
endometrial carcinomas.
2. Meterials and Methods
2.1. Clinical Samples. Formalin-fixed, paraﬃn-embedded
tissues of 57 cases and frozen tissues of 15 cases of endome-
trial carcinomas were retrieved for methylation study and
mRNA expression analysis. 12 cases of normal endometrium
were retrieved for methylation study. In 23 of the 57 carci-
noma cases being studied, their corresponding nonneoplastic
endometrium was retrieved for mRNA expression analysis.
All specimens of tissues were collected at the Department
of Pathology, Queen Mary Hospital, The University of Hong
Kong. Prior to DNA and RNA extraction, haematoxylin, and
eosin-stained section was reviewed to confirm histological
diagnosis and purity of the sample. Only samples with more
than 75% cancer cells were used.
2.2. DNA Extraction and Bisulphite Modification of Genomic
DNA. Genomic DNA was isolated from paraﬃn-embedded
tissue by phenol-chloroform extraction after protease K
digestion. Conversion of unmethylated cytosine residues
in the genomic DNA to uracil by sodium bisulphite was
performed as described previously in [24]. 5 μg of DNA was
used in the sodium bisulphate conversion. The QIAEX II kit
(QIAGEN) was used to purify the converted DNA according
to the manufacturer’s instructions.
2.3. Methylation-Specific Polymerase Chain Reaction (MS-
PCR). The methylation and unmethylation-sensitive
primers used in this study have been described previously
[21] and were shown in Table 1. The primers amplify
a CpG-island located at about 500 bp upstream to the
transcription start site of SOX2 (nm 0003106) [21]. 1.5 μl
of bisulfite-converted DNA was amplified in a 25 μl reaction
mixture containing 200 μM dNTPs, 10X reaction buﬀer,
2.5 mM MgCL2, 10 pM forward and reverse primers, and 1 U
of FastTaq (Roche). Bisulfite-converted normal lymphocyte
DNA methylated in vitro with Sssl methyltransferase
was used as positive control while water was used as
no-template controls. The MS-PCR was conducted as
following: predenatured for 4 min at 94◦C, then at 94◦C for
30 seconds, 55◦C for 30 seconds, 72◦C for 30 seconds for 40
cycles, and finally a 10-min extension at 72◦C. Polymerase
chain reaction products were separated on 2% Tris-borate
EDTA agarose gels, stained with ethidium bromide, and
visualized under a UA transilluminator. Cases detected with
the presence of methylated alleles were repeated once for
confirmation.
2.4. RNA Extraction and cDNA Synthesis. RNA was isolated
from paraﬃn-embedded tissue by TRIZOL (Invitrogen)
according to the manufacturer’s instructions. First-strand
cDNA was synthesized from 2.5 μg total RNA with oligo-
dTprimer and SuperScript III reverse transcriptase (Invitro-
gen) according to the manufacturer’s instructions.
2.5. Quantitative Real-Time Reverse Transcriptase-Polymerase
Chain Reaction. The mRNA expression of SOX2 was inves-
tigated using quantitative real-time reverse transcriptase-
polymerase chain reaction (RT-PCR). Primers were designed
specific to the SOX2 gene. Prime sequences for SOX2
and GAPDH (as internal control) are listed in Table 2.
Quantitative real-time RT-PCR was performed in a 10 μl
reaction, which included 1 μl of cDNA template, 10 pM
of each forward and reverse primer, and 5 μl iTaq SYBR
Green Supermix with Rox (Bio-rad). Each PCR reaction
was optimized to ensure that a single PCR product was
amplified and no product corresponding to prime-dimer
pairs was present. PCR reactions of each template were
performed in duplicate in one 96-well plate. The thermal
cycling conditions comprised an initial denaturation step at
95◦C for 10 min and 40 cycles at 95◦C for 15 sec, and 58◦C for
1 min. The expression of SOX2 was normalized with respect
to that of GAPDH.
2.6. Immunohistochemistry. Immunohistochemistry was
performed as previously described in [25]. Paraﬃn sections
4 μm thick was deparaﬃnized followed by antigen retrieval
using microwave treatment. Immunohistochemistry was
performed using the streptavidin-biotin complex immu-
noperoxidase method (Dako, Glostrup, Denmark). Mono-
clonal primary antibodies for estrogen receptor (ER) (Dako)
and progestogen receptor (PR) (Zymed Laboratories, San
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Table 1: Sequences of primers used in SOX2 methylation-specific PCR.
Primer Primer sequence (5′ to 3′) Product size (bp) Ref.
SOX2 promoter MSP-M
Forward TGTTTATTTATTTTTTTCGAAAAGGCG 206 [21]
Reverse GAACCCAACCTCGCTACCGAA
SOX2 promoter MSP-U
Forward TGTTTATTTATTTTTTTTGAAAAGGTG 208 [21]
Reverse CTCAAACCCAACCTCACTACCAA
Table 2: Sequences of primers used in quantitative Real-Time RT-PCR study.
Primer Primer sequence (5′ to 3′) Product size (bp) Ref.
SOX2
Forward CGAGATAAACATGGCAATCAAAAT 85 [21]
Reverse AATTCAGCAAGAAGCCTCTCCTT
GAPDH
Forward TCCATGACAACTTTGGTATCGTG 72 [21]
Reverse ACAGTCTTCTGGGTGGCAGTG
Francisco, CA) were applied, both at 1 : 150 dilution, and
incubated overnight at 4◦C. A case of breast cancer was used
as positive control in each batch of experiment. Negative
control was prepared by replacing the primary antibody
with Tris-buﬀered saline. Assessment of immunoreactivity
was performed independently by two pathologists according
to percentage of immunor active nuclei: 1: 1–25%; 2:
26%–50%; 3: 51–75%; 4: 76–100%.
2.7. Statistical Analyses. Statistical analysis was performed
using the Statistical Package Service Solution software (SPSS
version 16. 0). The association between methylation status
and clinicopathological parameters was tested by chi-square
test. The association between methylation status and mRNA
expression level was analyzed using Spearman correlation
test. For mRNA quantitative analysis, the relative gene
expression between groups was compared with unpaired t-
test (Mann-Whitney test). The association between methy-
lation status and ER/PR immuno-scores was analyzed using
Pearson correlation test. P values less than.05 were consid-
ered statistically significant with two-tailed test.
3. Results
3.1. Promoter Region of SOX2 Is Hypermethylated in Endome-
trial Carcinoma. In a previous study of methylation status
of SOX2 in gestational trophoblastic diseases, we identified
a CpG island upstream of the transcription start site of
SOX2 [21]. The methylation frequency of this CpG island in
72 cases of endometrial carcinoma and 12 cases of normal
endometrium was assessed by MS-PCR. Hypermethylation
of the SOX2 promoter was observed in 37.5% (27/72)
of endometrial carcinomas, and 8.3% (1/12) of normal
endometrial tissues (Table 3 and Figure 1(a)). Therefore,
more frequent hypermethylation in SOX2 promoter in
endometrial cancers than in normal endometrial tissues was
observed (P = .0472, chi-square test; Table 3). Moreover,
when the cancer samples were grouped according to their
histological subtypes, we observed a trend of more frequent
SOX2 promoter hypermethylation in type II (serous and
clear cell subtypes) (8/14, 57.1%) than in type I cancers
(endometrial subtype) (16/48, 33.3%) though statistical
significance was not reached (P = .108; Table 4). No
correlation was observed, however, between methylation
status with histological grade/ stage/ myometrial invasion/
vascular invasion/ age (Table 4).
SOX2 methylation status correlated with PR expression
(Pearson correlation 0.377, P = .033) but not with ER
expression. Kaplan-Meier analysis also demonstrated a sig-
nificant correlation between SOX2 methylation and shorter
overall survival (Figure 1(b); P = .046, log-rank test).
3.2. SOX2 mRNA Expression Is Lower in Endometrial Carci-
nomas Than in Their Normal Counter Parts and Is Correlated
with the Methylation Status in Carcinomas. Out of the
72 cases of endometrial carcinomas tested with MS-PCR,
23 cases have corresponding nonneoplastic endometrium
available. As shown in Figure 2, SOX2 mRNA level was
significantly reduced in endometrial carcinoma compared
with normal tissues of the same patients (P = .045
Mann-Whitney U test; Figure 2). Moreover, there was a
significant correlation between SOX2 mRNA expression
and hypermethylation of SOX2 in endometrial carcinomas
samples (Spearman correlation coeﬃcient = 0.470, P =
.024).
4. Discussion
In this study we tried to answer the question whether the
stemness-related transcription factor gene SOX2 expression
is aﬀected by promoter methylation in endometrial cancer.
Epigenetic gene silencing through DNA methylation has
been suggested to be one of the important steps dur-
ing endometrial carcinogenesis [23, 24, 26–28]. Promoter
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Table 3: Correlation of methylation status of the SOX2 gene in endometrial carcinomas and normal endometrial tissues.
Normal endometrial tissue Endometrial carcinoma P value (chi square)
Status Frequency (%) Frequency (%)
Methylated 1 (8.3%) 27 (37.5%)
.0472Unmethylated 11 (91.7%) 45 (62.5%)
Total 12 72
NE1 NE2 T1 T2 T3 T4
M U M U M U M U M U M U
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Figure 1: (a) Representative examples of methylation-specific PCR
on SOX2 in endometrial carcinomas (T), and in normal endome-
trial tissue (NE), demonstrating methylated (M) and unmethylated
(U) alleles. (b) Survival curves of patients classified according to the
presence or absence of methylated SOX2 allele.
hypermethylation of RASSF1A, metallothionein 1E, and
related tumor-suppressor genes have been found to correlate
with clinicopathological parameters in endometrial cancer
[23, 26, 28]. On the other hand, hypomethylation is also
found to be important in regulating the expression of the
S100A4 gene in endometrial cancer [27]. Here, our results
suggest more frequent hypermethylation events, at least in
the investigated CpG islands of SOX2 gene, in endometrial
cancer samples than in normal endometrium. Moreover,
hypermethylation of SOX2 promoter was correspondingly
matched by a decrease of SOX2 mRNA level in the samples.
Moreover, analysis on patients’ survival also linked hyper-
methylation of SOX2 with worse clinical outcome. Taken
together, our findings support the possibility that SOX2
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Figure 2: Relative SOX2 expression in endometrial carcinomas and
in normal endometrial tissue.
gene hypermethylation and downregulation contributes to
endometrial carcinogenesis.
Notably, the frequency of hypermethylation in cancer
samples was not high (37.5%). This may suggests that other
genetic or epigenetic events other than SOX2 downregulation
contribute to endometrial carcinogenesis. Moreover, hyper-
methylation is a dynamic process. It may exist in early stages
of endometrial carcinogenesis such as the precursor lesions
and may have reverted to unmethylated state by the time
carcinoma is developed. It is also possible that SOX2 was
downregulated by hypermethylation of other CpG islands in
the promoter regions of SOX2 that were not tested in this
study. In fact, the CpG island investigated in this study lies
at about 200 bp upstream of the transcription start site [21]
and CpG islands further upstream may exist (CpG search
analysis, data not shown). It is our next aim to study the
methylation pattern in CpG islands further away from the
transcription start site.
It is interesting to note that, among all clinicopatho-
logical parameters examined, hypermethylation of SOX2
promoter was linked marginally to histologic subtypes, being
relatively more common in type II serous and clear cell
adenocarcinomas. This finding further supports the notion
that type I and type II endometrial cancers represent two
diﬀerent malignancies with diﬀerent pathologically courses
[4]. Indeed, we have reported earlier the significantly more
frequent RASSF1A hypermethylation in type I endometrioid
carcinomas when compared with the type II carcinomas
[23].
Obstetrics and Gynecology International 5
Table 4: Correlation of SOX2 methylation status with clinicopathological features in endometrial cancers.
Clinicopathological Features Presence of methylated alleles Absence of methylated alleles P-value
Cases (%) Cases (%)
Histological type
Endometrioid 16 (66.7) 32 (84.2)
.108
Serous/CCC 8 (33.3) 6 (15.8)
Grade
Low (1) 7 (29.2) 15 (39.5)
.409
High (2-3) 17 (70.8) 22 (60.5)
Stage
I 19 (79.2) 32 (84.2)
.613
II–IV 5 (20.8) 6 (15.8)
Myometrial invasion
<1/2 8 (72.7) 27 (81.8)
.517≥1/2 3 (27.3) 6 (18.2)
Vascular invasion
Negative 12 (80.0) 27 (73.0)
.596
Positive 3 (20.0) 10 (27.0)
Involving cervix
Negative 13 (86.7) 34 (91.9)
.962
Positive 2 (13.3) 3 (8.1)
Age
<45 9 (36.0) 10 (26.3)
.413≥45 16 (64.0) 28 (73.7)
There was another interesting observation that SOX2
methylation was weakly correlated with PR expression.
Progesterone deficiency relative to estrogen level has been
considered as a risk factor for endometrial cancer [29]. High
PR expression is usually considered as a good prognostic
marker for endometrial cancer [30]. It is hence intriguing
that SOX2 methylation was found to correlate with shorter
survival (Figure 1(b)) but also with higher PR level. It is
possible that other mechanisms related to hypermethylation
of SOX2 may contribute to poor survival independent of
hormonal eﬀects by surmounting the beneficial eﬀect of
PR. For instance, suppression of SOX2 has been reported
to facilitate overcoming cell-cycle arrest and apoptosis [14].
Moreover, there are at least two distinct functional isoforms
of PR, PR-A, and PR-B, which are derived from the same
gene through alternative transcription start sites [31]. It
has been shown in mice that PR-B, in the absence of PR-
A, actually promotes cell proliferation in the presence of
estrogen alone or estrogen and progesterone simultaneously
[32]. It is therefore imperative to distinguish PR-A and PR-
B in human immunohistochemical studies. In fact, in a
recent immunohistochemical investigation conducted in 315
endometrioid endometrial cancer patients, a ratio of PR-
A/PR-B < 1 was associated with shorter survival, suggesting
PR-B may correlate with poor prognosis [33]. It is important
to further our investigation on the relationship between
SOX2 methylation and the statuses of both PR isoforms.
It is currently unclear why SOX2, a transcription factor
important for self-renewal and pluripotency of stem cells,
is downregulated in endometrial cancers. In fact, a meta-
analysis of publicly available gene expression data suggested
that at least one of the four pluripotency factors Oct3/4,
SOX2, Klf4, and c-myc is overexpressed in 18 out of 40
cancer types [34]. It was argued that overexpression of the
four factors may contribute to the pathological self-renewal
characteristics of cancer stem cells. However, overexpression
of SOX2 was not observed in endometrial cancer in the
analysis [34]. Our observation that SOX2 was downregulated
in endometrial cancer actually concurs with the mentioned
analysis. Moreover, SOX2 downregulation has been found to
be frequent in clinical samples, cancer cell lines and primary
cultures of human cancers such as choriocarcinomas [21]
and gastric cancer [14]. In choriocarcinoma cell lines,
SOX2 expression is restored following treatment to 5-Aza-
2′-deoxycytidine and/or Trichostatin A, demethylation and
histone deacetylase inhibitors respectively, and the eﬀect was
synergistic [21]. On the other hand, when forced to express
SOX2, gastric cancer lines were arrested in G1/S transition
and undergone apoptosis [14]. Two additional lines of
evidence further support that downregulation of SOX2
may be involved in early stages of gastric carcinogenesis.
Downregulation of SOX2 could be detected in precursor
lesions of gastric cancer such as intestinal metaplasia [13]
and Helicobacter pylori infection, a strong risk factor of
gastric cancer, could induce intestinal metaplasia through
inhibition of SOX2 expression [35]. It is possible that SOX2
also participate in the early carcinogenesis of endometrial
cancer via interaction with other risk factors.
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5. Conclusion
In summary, hypermethylation in association with reduced
expression of SOX2 was demonstrated in endometrial carci-
noma. Stem cell transcription factors are likely to play a role
in endometrial carcinogenesis.
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